| Drug
safety advice |
|
•
|
Methylphenidate:
updated guidance on safe and effective use in ADHD |
|
•
|
Atomoxetine:
risk of psychotic or manic symptoms |
|
•
|
Antipsychotics:
use in elderly patients with dementia |
|
•
|
Exenatide
(Byetta): risk of severe pancreatitis and renal failure |
|
•
|
Bisphosphonates:
atypical stress fractures |
| Yellow
Card scheme update |
|
•
|
Adverse
drug reactions in focus: progressive multifocal luekoencephalopathy
|
| Hot
topic |
|
•
|
Public
perception of herbal medicines |
|
Stop
Press
|
|
•
|
Efalizumab
(Raptiva): recommendation to suspend marketing authorisation |
|
•
|
Patient-controlled
analgesia extension sets: risk of inadequate pain relief |
|
•
|
Effects
of MRI on implantable drug pumps |
|
•
|
Oral
bowel cleansing solutions: risk of harm |
| Other
information from the MHRA |
|
•
|
Patient
Information Leaflets of the month: smoking-cessation aids |
|
•
|
Consultation:
changes to legislation and working during an influenza pandemic |
